All News

PARP inhibitors used alongside immunotherapy may help stimulate the immune response to cancer cells by attracting immune cells to the tumor.

Top news of the day from across the health care industry.

The study was the first to compare patients with hepatitis C treated with direct-acting antiviral drugs and those untreated for long-term risks.

In late 2018, Pharmacy Times surveyed readers to determine their satisfaction levels with their jobs and salaries as pharmacists.

Stem cell transplantation found to provide greater protection than disease-modifying therapy against progression of relapsing-remitting multiple sclerosis.

Vaccine misinformation is part of the growing problem that is creating a public health crisis, especially surrounding the global measles outbreak.

Dupilumab is now the first biologic therapy approved for the patient population.

There has been mixed evidence regarding whether there is an association between hormone replacement therapy (HRT) and Alzheimer disease.

The ever-growing price tag for new specialty drugs is testing the limits of the health care system to afford these revolutionary therapies.

With this approval, dupilumab (Dupixent) offers a biologic therapy option for patients 12 to 17 years of age who have moderate-to-severe atopic dermatitis.

What is causing the mysterious pain in this man's leg?

Top news of the day from across the health care industry.

M restricta was elevated in patients with Crohn disease carrying a genetic variation known as the IBD CARD9 risk allele.

Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.

The findings of the study were presented in an oral abstract presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, Washington.

The FDA recently published an updated draft guidance on the naming of biologics, biosimilars, and interchangeable biosimilars.

With this approval, atezolizumab plus nab-paclitaxel is the first cancer immunotherapy regimen to be approved for breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

Dupilumab (Dupixent, Regeneron and Sanofi) would be the first FDA-approved biologic for the treatment of severe chronic rhinosinusitis with nasal polyps.

Dupilumab (Dupixent, Regeneron and Sanofi) would be the first FDA-approved biologic for the treatment of severe chronic rhinosinusitis with nasal polyps.

Top news of the day from across the health care industry.

Top news of the week from Specialty Pharmacy Times.

If approved, rilpivirine plus cabotegravir would be the first monthly dosing option for adult patients with HIV.

Recently approved by the US Food and Drug Administration (FDA), the Biktarvyregimen is indicated for the treatment of adults with HIV-1 who have no history of antiretroviral therapy.

An individual treated for HIV is believed to be in long-term remission, according to experts in the United Kingdom. 'The London Patient’ is only the second documented case of sustained remission for HIV infection.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Venetoclax (Venclexta) plus obinutuzumab (Gazyva) is being developed for patients with previously-untreated chronic lymphocytic leukemia and co-existing medical conditions.

The supplemental new drug application for venetoclax in combination with obinutuzumab is being reviewed under the FDA’s Real-Time Oncology Review pilot program for patients with previously-untreated chronic lymphocytic leukemia.